Lexaria Bioscience
LEXX
Lexaria Bioscience (LEXX) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Maintained | Buy | $1.50 from $4.00 | Dec 26, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $4.00 from $5.00 | Jul 29, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $5.00 from $7.00 | Jul 1, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $7.00 from $10.00 | Jan 24, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $10.00 | Dec 2, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $10.00 | Nov 25, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $10.00 | Jul 18, 2024 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $10.00 | Jul 10, 2024 |
| Maxim Group | Maintained | Buy | $12.00 from $3.00 | Mar 5, 2024 |
| Maxim Group | Initiated Coverage | Buy | $2.00 | Jul 21, 2023 |
Frequently asked questions
What is the latest analyst rating on LEXX?
On Dec 26, 2025, HC Wainwright & Co. maintained Lexaria Bioscience at Buy with a price target of $1.50.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.